About the Company

Cellect Biotechnology (NasdaqGS: APOP; TASE: APOP) is developing technologies for companies in the regenerative medicine space. The Company’s platform technology Powered by CellectTM is designed to functionally select human stem and progenitor cells from a mixed population of cells in order to optimize allogeneic stem cell transplantation (alloHCT) and reduce the risk of graft-versus-host disease (GvHD). Cellect has initiated a Phase I/II trial in Israel evaluating the safety and efficacy of this technology in leukemia patients undergoing alloHCT. The Company plans to hold a pre-IND meeting with the FDA in the first half of 2017. The ongoing trial could serve as an important validation for this platform technology, which has broad potential application beyond this particular setting in large diseases such as type 1 diabetes, Crohn’s disease, psoriasis, and lupus.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research